📊 NXL Key Takeaways
Is Nexalin Technology, Inc. (NXL) a Good Investment?
Nexalin is a pre-revenue stage medical device company with unsustainable cash burn of $1.7M per quarter against only $14.9K in quarterly revenue, resulting in negative operating cash flow and a sub-4 month cash runway at current burn rate. Despite exceptional 87.8% gross margin, operating losses of $2.1M dwarf revenue generation, indicating the company faces near-term solvency risk without significant capital infusion or dramatic revenue acceleration.
Nexalin shows very high gross margins and minimal leverage, but its revenue base remains immaterial relative to extremely high operating losses and deeply negative free cash flow. With only ~$0.65M in cash against a ~$5M annual operating cash burn, liquidity risk and likely dilution are high. Fundamentals need clear evidence of sustained revenue traction and cost discipline before the profile improves.
Nexalin Technology, Inc. Key Strengths (NXL)
- Strong gross margin of 87.8% indicates product-market value proposition
- Zero debt and clean capital structure with $1.2M cash on hand
- Exceptional 3,760.8% YoY revenue growth (though from negligible base of $14.9K)
- High gross margin (~80%) suggests attractive unit economics
- Low leverage with no long-term debt
- Strong current ratio indicates limited near-term payables pressure
NXL Stock Risks: Nexalin Technology, Inc. Investment Risks
- Critical cash burn: -$1.7M operating cash flow vs. $1.2M total cash = <4 months runway
- Severe operating losses of -$2.1M on minimal revenue creates -14,179.9% operating margin
- Pre-commercial stage with no evidence of sustainable path to profitability or significant customer adoption
- Zero insider Form 4 filings in 90 days suggests lack of management confidence or activity
- Severe operating losses and deeply negative FCF
- Limited cash runway implying imminent capital raise/dilution risk
- Revenue base remains tiny despite YoY growth
Key Metrics to Watch
- Quarterly revenue run rate and customer acquisition trends
- Cash balance and monthly burn rate to track solvency runway
- Operating expense reductions or capital raise announcements
- Quarterly revenue
- Operating cash flow (burn rate)
Nexalin Technology, Inc. (NXL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.07x current ratio provides a solid financial cushion.
NXL Profit Margin, ROE & Profitability Analysis
NXL vs Healthcare Sector: How Nexalin Technology, Inc. Compares
How Nexalin Technology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nexalin Technology, Inc. Stock Overvalued? NXL Valuation Analysis 2026
Based on fundamental analysis, Nexalin Technology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nexalin Technology, Inc. Balance Sheet: NXL Debt, Cash & Liquidity
NXL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nexalin Technology, Inc.'s revenue has declined by 77% over the 5-year period, indicating business contraction. The most recent EPS of $-0.83 indicates the company is currently unprofitable.
NXL Revenue Growth, EPS Growth & YoY Performance
NXL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.0K | -$2.0M | $-0.11 |
| Q3 2025 | $18.1K | -$2.3M | $-0.13 |
| Q2 2025 | $26.8K | -$1.3M | $-0.10 |
| Q1 2025 | $41.0K | -$1.0M | $-0.14 |
| Q3 2024 | $24.1K | -$2.3M | $-0.23 |
| Q2 2024 | $26.8K | -$822.4K | $-0.11 |
| Q1 2024 | $30.6K | -$748.4K | $-0.10 |
| Q3 2023 | $24.1K | -$135.4K | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nexalin Technology, Inc. Dividends, Buybacks & Capital Allocation
NXL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nexalin Technology, Inc. (CIK: 0001527352)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NXL
What is the AI rating for NXL?
Nexalin Technology, Inc. (NXL) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NXL's key strengths?
Claude: Strong gross margin of 87.8% indicates product-market value proposition. Zero debt and clean capital structure with $1.2M cash on hand. ChatGPT: High gross margin (~80%) suggests attractive unit economics. Low leverage with no long-term debt.
What are the risks of investing in NXL?
Claude: Critical cash burn: -$1.7M operating cash flow vs. $1.2M total cash = <4 months runway. Severe operating losses of -$2.1M on minimal revenue creates -14,179.9% operating margin. ChatGPT: Severe operating losses and deeply negative FCF. Limited cash runway implying imminent capital raise/dilution risk.
What is NXL's revenue and growth?
Nexalin Technology, Inc. reported revenue of $15.0K.
Does NXL pay dividends?
Nexalin Technology, Inc. does not currently pay dividends.
Where can I find NXL SEC filings?
Official SEC filings for Nexalin Technology, Inc. (CIK: 0001527352) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NXL's EPS?
Nexalin Technology, Inc. has a diluted EPS of $-0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NXL's fundamental grade?
Based on our AI fundamental analysis in May 2026, Nexalin Technology, Inc. has a D grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NXL stock overvalued or undervalued?
Valuation metrics for NXL: ROE of -72.6% (sector avg: 15%), net margin of -14,025.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NXL's AI grade for 2026?
Our dual AI analysis gives Nexalin Technology, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NXL's free cash flow?
Nexalin Technology, Inc.'s operating cash flow is $-1.7M, with capital expenditures of N/A. FCF margin is -11,458.1%.
How does NXL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14,025.7% (avg: 12%), ROE -72.6% (avg: 15%), current ratio 4.07 (avg: 2).